{"DataElement":{"publicId":"2900495","version":"1","preferredName":"Patient T Stage Prostate Adenocarcinoma Clinical Trial Eligibility Criteria Status","preferredDefinition":"the status of a patient's prostate adenocarcinoma T stage in relation to clinical trial eligibility.","longName":"PT_TSTG_PR_CTEC_STAT","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2899606","version":"1","preferredName":"Patient T Stage Prostate Adenocarcinoma Clinical Trial Eligibility Criteria","preferredDefinition":"information relating to adenocarcinoma of the prostate (one of the most common malignant tumors afflicting men, the majority of which arise in the peripheral zone of the prostate gland) T stage (T refers to the extent of tumor involvement at the primary site) and determining whether a patient/participant is suitable for enrollment in a study according to protocol criteria and procedures.","longName":"PT_TSTG_PROSCA_CTEC","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2899604","version":"1","preferredName":"T Stage Prostate Adenocarcinoma  Clinical Trial Eligibility Criteria","preferredDefinition":"One criteria of the TMN staging system.  T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).:Prostate adenocarcinoma is one of the most common malignant tumors afflicting men. The majority of adenocarcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland. Grading of prostatic adenocarcinoma predicts disease progression and correlates with survival. Several grading systems have been proposed, of which the Gleason system is the most commonly used. Gleason sums of 2 to 4 represent well-differentiated disease, 5 to 7 moderately differentiated disease and 8 to 10 poorly differentiated disease. Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic adenocarcinoma. Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy. Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease. --2002:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C25728:C2919:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T Category","conceptCode":"C25728","definition":"One criteria of the TNM staging system. T refers to the extent of tumor involvement at the primary site (T, followed by a number indicating size and depth of invasion).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Prostate Adenocarcinoma","conceptCode":"C2919","definition":"An adenocarcinoma arising from the prostate gland.  It is one of the most common malignant tumors afflicting men.  The majority of adenocarcinomas arise in the peripheral zone and a minority occurs in the central or the transitional zone of the prostate gland.  Grading of prostatic adenocarcinoma predicts disease progression and correlates with survival.  Several grading systems have been proposed, of which the Gleason system is the most commonly used.  Gleason sums of 2 to 4 represent well-differentiated disease, 5 to 7 moderately differentiated disease and 8 to 10 poorly differentiated disease.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic adenocarcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BF0C3F2-7BB2-56AF-E040-BB89AD436B91","latestVersionIndicator":"Yes","beginDate":"2009-06-09","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-06-09","modifiedBy":"ONEDATA","dateModified":"2009-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BF0C3F2-7BC3-56AF-E040-BB89AD436B91","latestVersionIndicator":"Yes","beginDate":"2009-06-09","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-06-09","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2900493","version":"1","preferredName":"T Stage Prostate Eligibility Status","preferredDefinition":"the status of prostate adenocarcinoma T stage in relation to clinical trial eligibility.","longName":"TSTG_PRS_ELIG_STAT","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"5","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"T2","valueDescription":"T2","ValueMeaning":{"publicId":"2560156","version":"1","preferredName":"T2","longName":"2560156v1.00","preferredDefinition":"A general term that refers to a TNM finding of primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to primary tumor that is more than 2.0 cm, but not more than 5.0 cm in greatest dimension; for cutaneous melanoma it refers to primary tumor that is 1.01 to 2 mm in thickness, with or without ulceration; for colorectal cancer it refers to primary tumor with invasion into the muscularis propria; and for bladder cancer it refers to primary tumor with invasion into the muscle layer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T2 TNM Finding","conceptCode":"C48724","definition":"A general term that refers to a TNM finding of primary tumor growth beyond the level of in situ cancer, minimal subepithelial invasion, or minimal greatest diameter. The definition of T2 TNM finding depends on the specific type of cancer that it refers to; for example, for breast cancer it refers to primary tumor that is more than 2.0 cm, but not more than 5.0 cm in greatest dimension; for cutaneous melanoma it refers to primary tumor that is 1.01 to 2 mm in thickness, with or without ulceration; for colorectal cancer it refers to primary tumor with invasion into the muscularis propria; and for bladder cancer it refers to primary tumor with invasion into the muscle layer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B809-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6C15014C-72AA-DC52-E040-BB89AD4348BF","beginDate":"2009-06-11","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-06-11","modifiedBy":"ONEDATA","dateModified":"2009-06-11","deletedIndicator":"No"},{"value":"T1","valueDescription":"T1","ValueMeaning":{"publicId":"2560148","version":"1","preferredName":"T1","longName":"2560148v1.00","preferredDefinition":"T1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B801-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2023-09-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6C15014C-72B5-DC52-E040-BB89AD4348BF","beginDate":"2009-06-11","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-06-11","modifiedBy":"ONEDATA","dateModified":"2009-06-11","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2404650","version":"1","preferredName":"Status","preferredDefinition":"A condition or state at a particular time.","longName":"C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"005AD6E5-057F-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C15014C-7297-DC52-E040-BB89AD4348BF","latestVersionIndicator":"Yes","beginDate":"2009-06-11","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-06-11","modifiedBy":"SHIDED","dateModified":"2011-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811910","version":"1","longName":"Prostate","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Stage","type":"Preferred Question Text","description":"Stage","url":null,"context":"CTEP"}],"origin":"NCIC CRF:National Cancer Institute of Canada Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"6C15014C-72C0-DC52-E040-BB89AD4348BF","latestVersionIndicator":"Yes","beginDate":"2009-06-11","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-06-11","modifiedBy":"CAMPBELB","dateModified":"2011-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}